



PRESS RELEASE

Crucell to Present at Needham & Company Fourth Annual Biotechnology Conference, May 26

Leiden, The Netherlands, May 20, 2005 – Crucell N.V. (Euronext, NASDAQ: CRXL) has announced that its Chief Financial Officer, Leonard Kruimer, will present at the Annual Needham & Company Biotechnology Conference (May 25-26) in New York.

A live audio webcast will be available during the presentation at www.wsw.com/webcast/needham11/crxl/ and will be archived for a period of 90 days.

Mr. Kruimer will present on Thursday, May 26, at 9:30 AM Eastern time.

About Crucell

Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies. The company's development programs include collaborations with: sanofi pasteur for influenza vaccines; the U.S. National Institutes of Health for Ebola and malaria vaccines; and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its PER.C6[®] production technology. The company also licenses its PER.C6[®] technology to the biopharmaceutical industry. Licensees and partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit www.crucell.com.

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 15, 2005, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).

For further information please contact:

Crucell N.V.

Harry Suykerbuyk
Director Investor Relations and Corporate Communications
Tel +31-(0) 71-524 8718
h.suykerbuyk@crucell.com